華光新材(688379.SH):錫焊膏及預成型焊片等產品美國企業在全球市場具有較高的份額
格隆匯4月17日丨華光新材(688379.SH)在投資者互動平臺表示,公司一直重視產品的技術創新,多年來爲用戶提供綠色、高效、智能的先進焊接材料及其解決方案,推動下遊應用的國產化進程,目前公司涉及的國產替代產品主要有錫焊膏、預成型焊片、導電膠、銀銅鈦焊膏、鋁基複合釺料、助焊膏等,其中錫焊膏及預成型焊片等產品美國企業在全球市場具有較高的份額,我們將加大市場拓展,加快新產品驗證和產業化進程,逐步提升市場佔有率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.